Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.47 |
| ▸ | NOS1 | P29475 | 1/20 | 0.47 |
| ▸ | NOS2 | P35228 | 1/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 9/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | GRIK2 | Q13002 | 5/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.37 |
| ▸ | GRIK3 | Q13003 | 3/20 | 0.37 |
| ▸ | GRIK5 | Q16478 | 3/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 5/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.36 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1769498 | 1.00 | NOS3 (0.47) | NOS3NOS1NOS2GRIK1SLC7A5 | |
| SCHEMBL1768719 | 0.89 | GRIK1 (0.46) | NOS3NOS1NOS2GRIK1SLC7A5 | |
| SCHEMBL1768717 | 0.89 | GRIK1 (0.46) | NOS3NOS1NOS2GRIK1SLC7A5 | |
| SCHEMBL1768758 | 0.83 | NOS2 (0.53) | NOS3NOS1NOS2GRIK1GRIK2 | |
| SCHEMBL1768756 | 0.83 | NOS2 (0.53) | NOS3NOS1NOS2GRIK1GRIK2 | |
| SCHEMBL13585367 | 0.77 | GRIK1 (0.42) | NOS3NOS1NOS2GRIK1SLC7A5 | |
| SCHEMBL13585370 | 0.77 | GRIK1 (0.42) | NOS3NOS1NOS2GRIK1SLC7A5 | |
| SCHEMBL19757978 | 0.77 | ALDH1A1 (0.36) | — | |
| Aspartic Acid SCHEMBL14742179 | 0.75 | NOS3 (0.40) | NOS3NOS1NOS2GRIK1SLC7A5 | |
| SCHEMBL1527395 | 0.75 | NOS2 (0.65) | NOS3NOS1NOS2GRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637520-B2 | Template-fixed peptidomimetics with CXCR7 modulating activity | POLYPHOR AG (CH) | 2017-05-02 | — | — | US | disclosed |
| EP-2531520-B1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY | POLYPHOR AG (CH) | 2016-05-11 | — | — | EP | disclosed |
| US-20150307556-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY | POLYPHOR AG (CH) | 2015-10-29 | — | — | US | disclosed |
| US-9109009-B2 | Template-fixed peptidomimetics with CXCR7 modulating activity | POLYPHOR AG (CH) | 2015-08-18 | — | — | US | disclosed |
| US-8754038-B2 | Template-fixed peptidomimetics with CCR10 antagonistic activity | POLYPHOR AG (CH) | 2014-06-17 | — | — | US | disclosed |
| US-20130225506-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY | POLYPHOR AG (CH) | 2013-08-29 | — | — | US | disclosed |
| US-20120283168-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | POLYPHOR AG (CH) | 2012-11-08 | — | — | US | disclosed |
| WO-2011060832-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | POLYPHOR AG (CH) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283168-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | CCR10, CCR1, CCRL2 | NOS3 4757/4885NOS1 4500/4885NOS2 4664/4885 |
| US-20150307556-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY | CXCR1, CXCL12, CXCR6 | NOS3 3891/4885NOS1 3411/4885NOS2 3442/4885 |
| US-20130225506-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY | CXCR1, CXCL12, CXCR6 | NOS3 3615/4885NOS1 3131/4885NOS2 3170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.